3 Stocks Pushing The Health Care Sector Downward

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 112 points (-0.6%) at 17,638 as of Wednesday, May 4, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,014 issues advancing vs. 1,910 declining with 149 unchanged. The Health Care sector currently sits down 1.7% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the sector include Valeant Pharmaceuticals International ( VRX), down 4.5%, Shire ( SHPG), down 4.0%, Incyte ( INCY), down 3.8%, Biomarin Pharmaceutical ( BMRN), down 2.8% and Celgene ( CELG), down 2.4%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Eli Lilly and ( LLY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Eli Lilly and is down $1.46 (-1.9%) to $74.80 on average volume. Thus far, 1.8 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $74.78-$75.62 after having opened the day at $75.45 as compared to the previous trading day's close of $76.25. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $84.7 billion and is part of the drugs industry. Shares are down 9.5% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Eli Lilly and a buy, 1 analyst rates it a sell, and 4 rate it a hold. TheStreet Ratings rates Eli Lilly and as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full Eli Lilly and Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. 2. As of noon trading, AbbVie ( ABBV) is down $0.41 (-0.7%) to $61.36 on average volume. Thus far, 3.6 million shares of AbbVie exchanged hands as compared to its average daily volume of 7.0 million shares. The stock has ranged in price between $61.01-$61.65 after having opened the day at $61.30 as compared to the previous trading day's close of $61.77. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $99.0 billion and is part of the drugs industry. Shares are up 4.3% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate AbbVie a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates AbbVie as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full AbbVie Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. 1. As of noon trading, Medtronic ( MDT) is down $0.50 (-0.6%) to $78.94 on average volume. Thus far, 2.3 million shares of Medtronic exchanged hands as compared to its average daily volume of 5.5 million shares. The stock has ranged in price between $78.81-$79.42 after having opened the day at $79.39 as compared to the previous trading day's close of $79.44. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Medtronic plc manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $142.9 billion and is part of the health services industry. Shares are up 3.3% year-to-date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Medtronic a buy, 1 analyst rates it a sell, and 4 rate it a hold. TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Medtronic Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).